Cleveland, OH- based Juventas Therapeutics, a clinical-stage regenerative medicine company, has closed a $22.2 million Series B financing that was co-led by Triathlon Medical Venture Partners and New Science Ventures. All previous venture firms, including Fletcher Spaght Ventures, Reservoir Venture Partners and Early Stage Partners participated in the round. Also joining the syndicate are new [...]

SurgiQuest Inc. has closed on $19 million in new financing led by River Cities Capital Funds of Cincinnati. Boston-based Fletcher Spaght Ventures also contributed, as did CMEA Ventures, California Technology Ventures, Aphelion Medical Fund and other unnamed investors. SurgiQuest is based in Orange, Conn. The company is developing medical technologies for application in minimally invasive surgery.

HTG Molecular Diagnostics, a Tuscon-based provider of molecular technology, has raised $16.2 million in Series D financing. Investors include SR One, the corporate venture capital arm of GlaxoSmithKline, as well as Novo A/S, Fletcher Spaght Ventures, Merck Capital Ventures, Solstice Capital and Valley Ventures. Novo A/S led the round. Simeon George, partner at SR One will now join the company’s board.

PhaseBio Pharmaceuticals has closed a $25 million Series B round after adding $15 million in venture capital and nearly $500,000 in grants. The company, based in Malvern, Penn., is developing drugs to treat diabetes, metabolic disease and cardiovascular disease. Investors include Astellas Venture Management, Johnson & Johnson Development Corporation, Hatteras Venture Partners and Fletcher Spaght Ventures.